A Case of Coexistence of Bone Marrow-involved Refractory Marginal Zone B-Cell Lymphoma and Therapy-related Myelodysplastic Syndrome.
- Author:
Ilgeun SONG
1
;
Chan Jeoung PARK
;
Young Uk CHO
;
Eul Ju SEO
;
Je Hwan LEE
;
Chul Won SUH
;
Seongsoo JANG
Author Information
- Publication Type:Case Report
- Keywords: Bone marrow; Therapy-related myelodysplastic syndrome; Marginal zone B-cell lymphoma; Allogeneic hematopoietic stem cell transplantation
- MeSH: Alkylating Agents; Bone Marrow; Drug Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Korea; Lymphoma; Lymphoma, B-Cell, Marginal Zone*; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes*; Recurrence; Survival Rate; World Health Organization
- From:Laboratory Medicine Online 2016;6(2):98-101
- CountryRepublic of Korea
- Language:English
- Abstract: Recent advances in chemotherapy have led to increased survival rates for patients with hematologic malignancies. However, standard chemotherapies, including alkylating agents for non-Hodgkin lymphoma, could induce therapy-related myeloid neoplasms (t-MNs), a group of disorders categorized by the World Health Organization in 2008. Here, we report a case of coexistence of bone marrow (BM)-involved refractory marginal zone B-cell lymphoma (MZL) and therapy-related myelodysplastic syndrome (t-MDS). Simultaneous presence of refractory lymphoma and t-MN in the BM is rare, and this is the first report in Korea. The patient received allogeneic hematopoietic stem cell transplantation (HSCT) to cure both the MZL and t-MDS. Since the HSCT, he has been stable for 21 months without any evidence of recurrence.
